SARS-CoV-2 Infection Clinical Trial
Official title:
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center. The objective of this study is to understand whether and to what degree anti-SARS-CoV-2 antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the ESKD population.
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center. The objective of this study is to understand whether and to what degree anti-SARS-CoV-2 antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the ESKD population. Following informed consent, participants will undergo baseline serologic characterization for anti-SARS-CoV-2 IgM and IgG. The study is planned to align with the present wave of COVID-19. Enrollment will continue until the total sample size of 2500 is reached or until the study sponsor determines. Should there be a subsequent wave of COVID- 19, participants will be actively surveiled for evidence of SARS-CoV-2 infection and for COVID-19 disease. The relationship between baseline serologic status and subsequent infection/disease will be determined. This study will have 2 distinct phases. Phase 1 (baseline characterization) start will be triggered by the sponsor and may start at different times at the active sites. Participants will be consented and enrolled and blood will be collected for anti-SARS-CoV-2 antibodies. Phase 2: Start will be triggered by the sponsor in the fall of 2020 and each geographic study location may be triggered to start at separate times. Study participants will be followed prospectively for incidence and severity of COVID-19. Study visits will commence upon sponsor trigger and will occur once monthly for 4 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04593641 -
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
|
Phase 1 | |
Recruiting |
NCT05200754 -
Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04583995 -
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
|
Phase 3 | |
Recruiting |
NCT06255860 -
SARS-COV-2 Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study
|
||
Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
Recruiting |
NCT05012826 -
Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID
|
N/A | |
Completed |
NCT05007236 -
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
|
Phase 2 | |
Recruiting |
NCT06026514 -
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
|
Phase 1 | |
Completed |
NCT05523739 -
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
|
Phase 1 | |
Suspended |
NCT04738136 -
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
|
Phase 2 | |
Recruiting |
NCT04584658 -
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
|
||
Recruiting |
NCT04547114 -
Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
|
||
Completed |
NCT05119348 -
Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
|
N/A | |
Completed |
NCT05096962 -
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
|
||
Recruiting |
NCT04534400 -
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure
|
||
Completed |
NCT04527354 -
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
|
Phase 2 | |
Completed |
NCT04583982 -
ImmuneSense™ COVID-19 Study
|
||
Completed |
NCT05077176 -
Phase 3 Booster Vaccination Against COVID-19
|
Phase 3 | |
Completed |
NCT05584189 -
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
|
N/A |